Targeting Notch Signaling in Colorectal Cancer
- 259 Downloads
The activation of Notch signaling is implicated in tumorigenesis in the colon due to the induction of pro-survival signaling in colonic epithelial cells. Chemoresistance is a major obstacle for treatment and for the complete eradication of colorectal cancer (CRC); hence, the inhibition of Notch is an attractive target for CRC and several groups are working to identify small molecules or monoclonal antibodies that inhibit Notch or its downstream events; however, toxicity profiles in normal cells and organs often impede the clinical translation of these molecules. Dietary agents have gained momentum for targeting several pro-survival signaling cascades, and recent studies demonstrated that agents that inhibit Notch signaling result in growth inhibition in preclinical models of CRC. In this review, we focus on the importance of Notch as a preventive and therapeutic target for colon cancer and on the effect of WA on this signaling pathway in the context of colon cancer.
KeywordsNotch-1 Chemoresistance Dietary agent Prevention Treatment Colon cancer
This study was supported by NIH Grant 1R01CA185972-01.
Compliance with Ethics Guidelines
Conflict of Interest
Suman Suman, Trinath P. Das, Murali. K. Ankem, and Chendil Damodaran declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 62.••Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014;141(2):140–9. This recent review article describes the role of Notch signaling in cancer as well as the agents in use to target Notch signaling in different cancer types.PubMedCrossRefGoogle Scholar
- 63.••Timme CR, Gruidl M, Yeatman TJ. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells. Apoptosis. 2013;18(10):1163–74. It is a interesting study where authors have shown gamma-secretase inhibition resulted in decrease in oxaliplatin-induced apoptosis. This study warrants caution while treating colon cancer with the combination of GSIs and chemotherapy.PubMedCrossRefGoogle Scholar
- 65.Cooper K et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess. 2010;14(32):1–206.Google Scholar
- 74.••Vyas AR, Singh SV. Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone. AAPS J. 2014;16(1):1–10. The authors have discussed the in vivo potential and molecular targets of WA contributing to its anticancer effects.PubMedPubMedCentralCrossRefGoogle Scholar
- 82.Sabina PE, Chandel S, Raool KM. Evaluation of analgesic, antipyretic and ulcerogenice effect of Withaferin A. Int J Integr Biol. 2009;6(2):52–6.Google Scholar
- 87.•Lee J, Sehrawat A, Singh SV. Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer Res Treat. 2012;136(1):45–56. Authors have shown the effect of WA in breast cancer cells. They showed activation of Notch 2,4 and inactivation of Notch1 by WA. Notch 2 and Notch4 knockdown augmented WA mediated inhibition of cell migration.PubMedPubMedCentralCrossRefGoogle Scholar
- 88.•Zhang X et al. Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A. Gynecol Oncol. 2012;124(3):606–12. Authors have shown WA mediated downregulation of Notch1 and 3 in ovarian cancer cells. This downregulation correlated with induction of apoptosis and cell cycle arrest.PubMedPubMedCentralCrossRefGoogle Scholar